Navigation Links
Matthew B. Wiener, CEO of Pharmatech, Inc., Is Awarded the Cancer Leadership Award From the Colorado Cancer Coalition

DENVER, Oct. 2 /PRNewswire/ -- Matthew B. Wiener, PharmD, Chief Executive Officer of Pharmatech, Inc., was recently awarded the Outstanding Cancer Leadership Award from the Colorado Cancer Coalition. The award is being presented to Dr. Wiener for his development of the Just-In-Time (JIT) enrollment methodology for cancer clinical trials. Dr. Wiener will accept his award on the evening of October 6th, at the St. Mary's Cancer Center, which will take place during the Colorado Cancer Summit, October 6th and 7th, in Grand Junction, Colorado.

The Just-In-Time methodology has been utilized at various Pharmatech research network sites within the state of Colorado as a means to increase enrollment in cancer clinical trials for rare disease indications. The JIT strategy puts the patient first in regards to enrolling into a clinical trial, as cancer patients are treated in a more efficient manner and drug sponsors see their trials completed in a shorter time frame. Matthew Wiener states that, "It is a high honor to receive such a distinguished award from the Colorado Cancer Coalition. Their recognition of our JIT program gives the program clout within the pharmaceutical and bioscience industries."

Matthew Wiener has dedicated the past 20 years to clinical research and his JIT program has been featured in abstracts and poster presentations at annual meetings, including the American Society of Clinical Oncology (ASCO) and the American Society of Hematology (ASH).

About Pharmatech, Inc.:

Pharmatech, headquartered in Denver, Colorado, is a Research Management Organization (RMO) dedicated to the highest quality of clinical research. Pharmatech provides services of a Site Management Organization (SMO) and a Contract Research Organization (CRO) with a focus in oncology clinical trials. Through an organized research network, the Company focuses on the development and utilization of therapeutic products among sponsors, investigators, and patients. For more information about Pharmatech, please visit

Key Words: Oncology, Clinical Trials, Cancer Patients, CRO, SMO, Just-In-Time, Colorado

SOURCE Pharmatech, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Genstructs Andrea Matthews Selected for Mass High Techs People to Watch Under 30
2. Cerimon Pharmaceuticals Names Matthew J. Meyer its General Counsel and Vice President of Business Development and Licensing
3. Cord Blood America CEO Matthew Schissler Interviewed by BIONOVA, Greeces Leading Biotech Magazine
4. Matthew B. Potter Joins Pressure BioSciences, Inc. as Vice President of Sales
5. Neurobiological Technologies Appoints Matthew M. Loar as Chief Financial Officer
6. Matthew J. Pfeffer Joins MannKind as Corporate Vice President and Chief Financial Officer
7. Cord Blood America CEO Matthew Schissler Says Operations Significantly Streamlined
8. BioSpecifics Technologies Corp. Announces Appointment of Dr. Matthew Geller to Board of Directors
9. BSP Pharma Inc., Makers of FlexNow(TM) Joint Formula Sign Distribution Deal with Vitamin Shoppe and GNC
10. The PLSG Invests $150,000 in Coventina Healthcare Enterprises, Inc., Its Eighth Company Relocation to Pittsburgh
11. Corium International, Inc., Announces $40 Million Financing led by Essex Woodlands Health Ventures
Post Your Comments:
(Date:6/27/2016)... 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or ... its major shareholders, Clean Technology Fund I, LP and ... based venture capital funds which together hold ... a fully diluted, as converted basis), that they have ... entire equity holdings in Biorem to TUS Holdings Co. ...
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... Parallel ... clinical trials, announced today the Clinical Reach Virtual Patient Encounter CONSULT module ... circle with the physician and clinical trial team. , Using the CONSULT module, patients ...
(Date:6/27/2016)...  Liquid Biotech USA , ... Sponsored Research Agreement with The University of Pennsylvania ... cancer patients.  The funding will be used to ... clinical outcomes in cancer patients undergoing a variety ... employed to support the design of a therapeutic, ...
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
Breaking Biology Technology:
(Date:4/15/2016)... CHICAGO , April 15, 2016  A ... companies make more accurate underwriting decisions in a ... offering timely, competitively priced and high-value life insurance ... health screenings. With Force Diagnostics, rapid ... and lifestyle data readings (blood pressure, weight, pulse, ...
(Date:3/31/2016)... , March 31, 2016   ... ("LegacyXChange" or the "Company") LegacyXChange is excited ... of its soon to be launched online site for ... ) will also provide potential shareholders a ... DNA technology to an industry that is notorious for ...
(Date:3/22/2016)... PUNE, India , March 22, 2016 ... new market research report "Electronic Sensors Market for ... Fingerprint, Proximity, & Others), Application (Communication & ... and Geography - Global Forecast to 2022", ... consumer industry is expected to reach USD ...
Breaking Biology News(10 mins):